

## Pathkind Labs & Roche Diagnostics to offer comprehensive diabetes and cardiac care

07 January 2023 | News

**Focusing on a marker instrumental in the management of cardiovascular diseases in Type 2 Diabetes patients**



Gurugram-based Pathkind Diagnostics is all set to transform diabetes care in India with Roche Diagnostics' cardiac biomarker- NTProBNP that is used in the management of Type 2 Diabetes (T2DM). NTProBNP is the gold-standard biomarker for detecting heart failure in patients and Roche Diagnostics is the only company to have received a claim extension allowing it to be used for identification of the risk of heart failure and other cardiovascular disease (CVD) risks in people living with T2DM.

With the incorporation of NTProBNP in diabetes management, Pathkind will be a leader in providing comprehensive and holistic diabetes and cardiac care.

Speaking on the occasion, Sanjeev Vashishta, MD & CEO Pathkind Labs said, "The co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality. The addition of this high-sensitivity NTProBNP test will assist healthcare professionals and patients in making important medical decisions."

Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets, said, "Incorporating NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management is critical and essential. In order to lower mortality and CVD events, it is crucial to screen people with T2DM for CVD risk, therefore our partnership with Pathkind will be a turning point in diabetes management."